

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61L 31/10, 31/16, 31/04	A1	(11) International Publication Number: WO 00/27445 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/US99/26556 (22) International Filing Date: 10 November 1999 (10.11.99) (30) Priority Data: 09/189,540 10 November 1998 (10.11.98) US 09/352,188 12 July 1999 (12.07.99) US (71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US]; One Scimed Place, Maple Grove, MN 55311-1566 (US). (72) Inventors: BOOCK, Robert, James; Apartment #304, 2260 South Plymouth Road, Minnetonka, MN 55305 (US). HERGENROTHER, Robert; 10423 Brown Farm Circle, Eden Prairie, MN 55347 (US). SLAIKEU, Paul, C.; 3594 Skyline Drive, Hayward, CA 94542 (US). WALLACE, Michael, P.; 3515 D Bernal Avenue, Pleasanton, CA 94566 (US). EDER, Joseph, C.; 23423 Toyonta Road, Los Altos, CA 94024 (US). BARRY, James, J.; 35 Jackson Circle, Marlborough, MA 01752 (US). ABRAMS, Robert, M.; 359 Redondo Terrace, Sunnyvale, CA 94086 (US). (74) Agents: BATT, Richard, R. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: BIOACTIVE COATING FOR VASO-OCCLUSIVE DEVICES (57) Abstract <p>This is a medical device for forming an embolism within the vasculature of a patient. More particularly, it is a vaso-occlusion device at least partially coated with a bioactive agent, a collagenous material, or a collagenous coating optionally containing or coated with other bioactive agents. A highly flexible vaso-occlusive device coated with such materials also forms a variation of the invention.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BIOACTIVE COATING FOR VASO-OCCLUSIVE DEVICES

FIELD OF THE INVENTION

5 This invention relates to a medical device for forming an embolism within the vasculature of a patient. More particularly, it is a vaso-occlusion device at least partially coated with a bioactive agent, a collagenous material, or a collagenous coating optionally containing or coated with other bioactive agents. A highly flexible vaso-occlusive device
10 coated with such materials also forms a variation of the invention.

BACKGROUND

Vaso-occlusive devices are surgical implants that are placed within open sites in the vasculature of the human body. The devices are introduced typically via a catheter to the
15 site within the vasculature that is to be closed. That site may be within the lumen of a blood vessel or perhaps within an aneurysm stemming from a blood vessel.

There are a variety of materials and devices which have been used to create such emboli. For instance, injectable fluids such as microfibrillar collagen, various polymeric foams and beads have also been used. Polymeric resins, particularly cyanoacrylate resins,
20 have been used as injectable vaso-occlusive materials. Both the injectable gel and resin materials are typically mixed with a radio-opaque material to allow accurate siting of the resulted material. There are significant risks involved in use of a cyanoacrylates, because of the potential for misplacement. Such a misplacement would create emboli in undesired areas. Cyanoacrylate resins or glues are somewhat difficult, if not impossible, to retrieve
25 once they are improperly placed.

Other available vaso-occlusive devices include mechanical vaso-occlusive devices. Examples of such devices are helically wound coils and braids. Various shaped coils have been described. For example, U.S. Patent No. 5,624,461, to Mariant, describes a three-dimensional in-filling vaso-occlusive coil. U.S. Patent No. 5,639,277, to Mariant et al.,
30 describes embolic coils having twisted helical shapes and U.S. Patent No. 5,649,949, to Wallace et al., describes variable cross-section conical vaso-occlusive coils. A random shape is described, as well. U.S. Patent No. 5,648,082, to Sung et al., describes methods for treating arrhythmia using coils which assume random configurations upon deployment

from a catheter. U.S. Patent No. 5,537,338 describes a multi-element intravascular
5 occlusion device in which shaped coils may be employed. Spherical shaped occlusive
devices are described in U.S. Patent No. 5,645,558 to Horton. Horton describes how one or
more strands can be wound to form a substantially hollow spherical or ovoid shape when
deployed in a vessel. U.S. Patent Nos. 5,690,666 and 5,718,711, by Berenstein et al., show
10 a very flexible vaso-occlusive coil having little or no shape after introduction into the
vascular space.

There are a variety of ways of discharging shaped coils and linear coils into the
human vasculature. In addition to those patents which apparently describe only the
physical pushing of a coil out into the vasculature (e.g., Ritchart et al.), there are a number
of other ways to release the coil at a specifically chosen time and site. U.S. Patent No.
15 5,354,295 and its parent, 5,122,136, both to Guglielmi et al., describe an electrolytically
detachable embolic device. That is to say that a joint between the pusher wire and the vaso-
occlusive portion dissolves or erodes when an electrical current is applied to the pusher
wire.

A variety of mechanically detachable devices are also known. For instance, U.S.
20 Patent No. 5,234,437, to Sepetka, shows a method of unscrewing a helically wound coil
from a pusher having an interlocking surface. U.S. Patent No. 5,250,071, to Palermo,
shows an embolic coil assembly using interlocking clasps that are mounted both on the
pusher and on the embolic coil. U.S. Patent No. 5,261,916, to Engelson, shows a
detachable pusher-vaso-occlusive coil assembly having an interlocking ball and keyway-
25 type coupling. U.S. Patent No. 5,304,195, to Twyford et al., shows a pusher-vaso-
occlusive coil assembly having an affixed, proximately extending wire carrying a ball on its
proximal end and a pusher having a similar end. The two ends are interlocked and
disengage when expelled from the distal tip of the catheter. U.S. Patent No. 5,312,415, to
Palermo, also shows a method for discharging numerous coils from a single pusher by use
30 of a guidewire which has a section capable of interconnecting with the interior of the
helically wound coil. U.S. Patent No. 5,350,397, to Palermo et al., shows a pusher having a
throat at its distal end and a pusher through its axis. The pusher sheath will hold onto the

end of an embolic coil and will then be released upon pushing the axially placed pusher
5 wire against the member found on the proximal end of the vaso-occlusive coil.

In addition, several patents describe deployable vaso-occlusive devices that have
added materials designed to increase their thrombogenicity. For example, fibered vaso-
occlusive devices have been described at a variety of patents assigned to Target
Therapeutics, Inc., of Fremont, California. Such vaso-occlusive coils having attached
10 fibers is shown in U.S. Patent Nos. 5,226,911 and 5,304,194, both to Chee et al. Another
vaso-occlusive coil having attached fibrous materials is found in U.S. Patent No. 5,382,259,
to Phelps et al. The Phelps et al. patent describes a vaso-occlusive coil which is covered
with a polymeric fibrous braid on its exterior surface. U.S. Patent No. 5,658,308, to
Snyder, is directed to a coil having a bioactive core.

15 In other attempts to increase thrombogenicity, vaso-occlusive coils have also been
treated with variety of substances. For instance, U.S. Patent No. 4,994,069, to Ritchart et
al., describes a vaso-occlusive coil that assumes a linear helical configuration when
stretched and a folded, convoluted configuration when relaxed. The stretched condition is
used in placing the coil at the desired site (via passage through the catheter) and the coil
20 assumes a relaxed configuration -- which is better suited to occlude the vessel -- once the
device is so-placed. Ritchart et al. describes a variety of shapes. The secondary shapes of
the disclosed coils include "flower" shapes and double vortices. The coils may be coated
with agarose, collagen, or sugar.

U.S. Patent No. 5,669,931, to Kupiecki, discloses coils that may be filled or coated
25 with thrombotic or medicinal material. U.S. Patent No. 5,749,894, to Engleson, discloses
polymer-coated vaso-occlusion devices. U.S. patent No. 5,690,671 to McGurk discloses an
embolic element which may include a coating, such as collagen, on the filament surface.

U.S. Patent No. 5,536,274 to Neuss shows a spiral implant which may assume a
variety of secondary shapes. Some complex shapes can be formed by interconnecting two
30 or more of the spiral-shaped implants. To promote blood coagulation, the implants may be
coated with metal particles, silicone, PTFE, rubber lattices, or polymers.

5 None of the above documents discuss vaso-occlusive devices such as those found below, and specifically not the preferred combination vaso-occlusive coils associated with the coating materials in the configuration disclosed herein.

5

SUMMARY OF THE INVENTION

The invention includes a vaso-occlusive device comprising: a) a biocompatible metal or polymer vaso-occlusive base member or structure, e.g., a coil or braid or aneurysm neck bridge; b) optional fibrous materials attached to the base member; c) an inner optional coating treatment or tie coating on said vaso-occlusive member; d) a collagenous outer coating and/or other natural or synthetic proteins one or more bioactive agents optionally associated with said collagenous outer layer. The vaso-occlusive member may be a coil, a braid, a sphere, or other shaped structure. In a preferred embodiment, the vaso-occlusive member is an elongated helical coil made up of a series of helical windings, for instance a cylindrical helical coil. Preferably, the coil is made of gold, rhenium, platinum, palladium, rhodium, ruthenium, stainless steel, tungsten and alloys, titanium/nickel and alloys thereof.

15

The optional, inner tie coating is a material suitable for providing a binding layer between the vaso-occlusive device and the outer collagenous or proteinaceous coating. Preferably, the inner coating is bonded to said vaso-occlusive member. The inner coating may be, for instance, of known silane coupling agents or primer polymer agents, e.g., low molecular weight polymer adhesives or the like. The inner coating may also be deposited on the member by plasma treatment or may simply be a plasma treatment of the type intended to etch the substrate. The inner coating may also include vapor-deposited polymers, e.g., polyxylylene and the like. Other methods for applying the thin polymeric inner coatings, e.g., by dipping or spraying dilute polymeric solution, may also be employed.

20

The vaso-occlusive device may include polymeric fibers in various configurations, e.g., tufted, looping, braided, etc. which are then coated with the proteinaceous matter.

25

The outer coating may be proteinaceous, preferably collagenous, in nature and may be applied either as a "neat" or substantially pure layer or may be used as a base or support for or in mixture with other components with a specific role, e.g., genes, growth factors, biomolecules, peptides, oligonucleotides, members of the integrin family, RGD-containing sequences, oligopeptides, e.g., fibronectin, laminin, bitronectin, hyaluronic acid, silk-elastin, elastin, fibrinogen, and other basement membrane proteins with bioactive agents.

30

Preferably, the outer coating comprises a photo-polymerizable collagen or other protein which will bind both with the inner tie layer and with the added bioactive agents.

The invention includes, as a variation, a combination of the vaso-occlusive base member, an inner optional tie coating; collagenous outer coating, and optionally one or more bioactive agents associated with said collagenous outer layer., applied to the base member in such a way that they do not substantially affect the physical attributes of the base member, e.g., its flexibility. Preferably, the various coatings do not affect the inherent shape of the vaso-occlusive member after deployment.

The invention further includes, as a variation, a combination of the vasoocclusive base member, an inner optional tie coating, and one or more bioactive agents applied directly to the base member. Again, such bioactive materials include genes, growth factors, biomolecules, peptides, oligonucleotides, members of the integrin family, RGD-containing sequences, oligopeptides, e.g., fibronectin, laminin, bitronectin, hyaluronic acid, silk-elastin, elastin, fibrinogen, and other basement membrane proteins with bioactive agents.

The invention involves a method for treating a vaso-occlusive device comprising (a) applying an inner tie coating for a vaso-occlusive device; and (b) applying an outer coating over said inner tie coating.

As will become apparent, preferred features and characteristics of one aspect of the invention are applicable to any other aspect of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, which are not to scale:

Figure 1 is a perspective view of one embodiment of the invention.

Figure 2 is a perspective view of another embodiment of the invention showing a coil having a permanently bonded inner coating of a thrombotic agent and a water-soluble, dissolvable outer coating of an anti-thrombotic agent.

DESCRIPTION OF THE INVENTION

This invention is a vaso-occlusive device having an outer coating of a collagen-based material or other bioactive material. It may have other functional drugs or proteins associated (chemically linked or physically mixed) with the collagen. The collagen-based material is for the purpose of enhancing the rate and density of the occlusion produced by the vaso-occlusive device at the selected body site and specifically to promote permanent cellular in-growth at that site. The therapeutics, drugs, or proteinaceous material associated with the collagenous material are placed in the collagen to provide specific effects outlined below.

As used, the outer, collagen-based or other bioactive-based coating is preferably placed over an inner tie layer coating or treatment. The binding layer preferably provides a layer contiguous to the vaso-occlusive device and the outer coating. The inner coating is generally bonded to said vaso-occlusive member. The inner coating may be of known silane coupling agents or primer polymer agents (e.g., low molecular weight polymer adhesives) or the like. The inner coating may also be deposited on the member by plasma treatment or may simply be a plasma treatment of the type intended to etch the substrate. The inner coating may also include vapor-deposited polymers, e.g., polyxyxylene and the like. Other methods for applying the thin polymeric inner coatings, e.g., by dipping or spraying dilute polymeric solution, may also be employed.

Preferably, the inner coating is permanently bonded to the coil and either chemically or physically bonded to the outer coating so that shortly after coil deployment,

the outer material can safely perform its intended purpose, *i.e.* beginning the healing cascade within the vessel.

Another suitable tie layer coating involves "plasma treatment" of coils. (See, e.g., co-pending USSN 08/598,325). These plasma-treated coils exhibit an amino-functionality which may be measured using known chemical methods. When the devices treated by this process are placed in a bloodstream, the amino-functionality results in a slight positive ionic charge on the surface of the fibers. This amino-functionality attracts platelets and thrombogenic proteins from the bloodstream. Plasma treatment may be carried out using e.g., a plasma generator such as that found in U.S. Patent No. 3,847,652. The plasma may comprise a nitrogen-containing gas, preferably those containing diatomic nitrogen or ammonia. Gas pressures are advantageously maintained at a very low level, e.g., no greater than about 5 millimeters of mercury, preferably from 0.1 to 2 millimeters of mercury.

The period of time in which the vaso-occlusive device is subjected to the plasma need not be great. That is to say that for most applied power settings below about 200 watts and in the radio frequency region between 1 and 50 megaHertz, the time of reaction need not be greater than 10 minutes to achieve the result described herein.

Other plasma treating steps which are intended to etch the substrate are also suitable for this invention.

Figures 1 and 2 show typical vaso-occlusive devices suitable for use with this procedure. Figure 1 shows atypical vaso-occlusive device (100). Vaso-occlusive device (100) is shown in Figure 1 to include a helically wound coil (102) having tips (104) to ease the potential of the component wire to cause trauma in a blood vessel. The device may include tufts or fiber bundles attached to it, so to increase the amount and volume of fiber held by the coil and thereby to promote overall thrombogenicity of the device. Typical of a vaso-occlusive device comprising a helical coil having attached fibrous elements such as shown in Figure 1 is found in U.S. Patent No. 5,226,911, to Chee et al, the entirety of which is incorporated by reference.

Figure 2 shows a vaso-occlusive device (200) comprising a helically wound coil (202), an inner tie coating (204) and an outer collagenous coating (206). The inner coating

is generally a substance, preferably proteinaceous, which is bound to the coil (202) and which is also bound, physically or chemically, to the outer collagenous covering (206).

The occlusion devices of the invention may be made using conventional equipment and procedures. For example, helical coils may be prepared by wrapping a suitable wire about a cylindrical or conical mandrel. The strand(s) are then placed axially through the core of the helix and, if a multiplicity of strands are employed, their ends may be bound by heat, adhesives, or mechanical means. Radial filaments may be attached to the windings of the helix by tying or with adhesives.

The polymeric materials used in the vaso-occlusive devices in Figures 1 and Figure 2 are known materials. They are those materials which are generally approved for use as implants in the body or could be so approved. They may be of polymers such as polyethylene, polyacrylics, polypropylene, polyvinylchloride, polyamides such as Nylon, polyurethanes, polyvinylpyrrolidone, polyvinyl alcohols, polyvinylacetate, cellulose acetate, polystyrene, polytetrafluoroethylene, polyesters such as polyethylene terephthalate (Dacron), silk, cotton, and the like. When the polymers are fibrous, they are often looped or tufted as shown in the drawings. Although it is not critical to this invention, they are usually assembled in bundles of 5 to 100 fibers per bundle. Preferred materials for the polymer component of vaso-occlusive devices comprise polyesters, polyethers, polyamides, and polyfluorocarbons. Especially preferred is polyethyleneterephthalate, sold as Dacron. Placing a protein-based covering on the fibers is a variation of the invention.

Another variation of the invention includes the specific use of polymers which evince an angiogenic response, preferably, biodegradable polymers, that are associated with the vaso-occlusive support base. By "associated" is meant that the material is tied to or is made to adhere to the vaso-occlusive support base. The composition may be a fabric or gauze-like structure. It may also be a non-woven or loose agglomeration of individual fibers. In general, they need to stay in place during the placement of the device in the body.

Preferably, the associated covering is a polymeric material such as a biodegradable polymer, e.g., polyglycolic acid, polylactic acid, reconstituted collagen, poly-*p*-dioxanone, and their copolymers such as poly(glycolide-lactide) copolymer, poly(glycolide-trimethylene carbonate) copolymer, poly(glycolide- ϵ -caprolactone) copolymer, glycolide-

trimethylene carbonate triblock copolymer, and the like. Mixtures of the noted polymers,
5 e.g., of polylactide and polyglycolide may also be used. The associated coverings may also
be used in conjunction with the bioactive coatings discussed elsewhere.

The coils (102 in Figure 1 and 202 in Figure 2) may be made of any of a wide
variety of biocompatible metals or polymers or carbon. In particular, the metals may be
selected from gold, rhenium, platinum, palladium, rhodium, ruthenium, various stainless
10 steels, tungsten, and their alloys, titanium/nickel alloys particularly nitinoltype alloys. The
preferred alloy is one comprising upwards of 90 percent platinum and at least a portion of
the remainder, tungsten. This alloy exhibits excellent biocompatibility and yet has
sufficient strength and ductility to be wound into coils of primary and secondary shape and
will retain those shapes upon placement of the vaso-occlusive device in the human body.
15 The diameter of the wire typically making up the coils is often in a range of 0.005 and
0.050 inches. The resulting primary coil diameter typically is in the range of 0.008 and
0.085 inches. Smaller coil diameters are used for finer problems and larger coil diameters
and wire diameters are used in larger openings in the human body. A typical coil primary
diameter is 0.015 and 0.018 inches. The axial length of a vaso-occlusive device may be
20 between 0.5 and 100 centimeters. The coils are typically wound to have between 10 and 75
turns per centimeter.

In addition to the coils shown in the Figures, the vaso-occlusive device may
comprise a substrate comprising a woven braid rather than the helical coil shown in those
Figures. The vaso-occlusive device may comprise a mixture of coil and braid. Indeed, it is
25 within the scope of this invention that a portion of the coil be polymeric or a combination
of metal and polymer.

It is further within the scope of this invention that the vaso-occlusive device
comprise shapes or structures other than coils or braids, for examples, spherical structures
and the like.

30 In one aspect of the present invention, the vaso-occlusive devices described above
and those similar to those specifically described above, are first optionally treated with a tie
layer coating and then subjected to treatment to provide the outer collagenous,
proteinaceous, or bioactive material layer. Preferably, neither the inner nor outer coatings

interfere with the shape of the coil after deployment. In one variation of the invention, the
5 outer layer is applied to the vaso-occlusive base without the inner tie layer, but is applied in
such an amount that the resulting assembly is not significantly more stiff than is the vaso-
occlusive device without the covering. That is to say, the coated device is not more than
35%, preferably not more than 15%, and most preferably not more than 5%, stiffer than is
the untreated device base. Preferably, the covering is less than about 1.0 mil, more
10 preferably less than about 0.5 mil in thickness.

When a collagen layer, the outer collagenous layer may be of a wide variety of
types, natural or synthetic, but preferably comprises a photo-polymerizable collagen which
will bind both with the inner tie layer and with the added bioactive agents. The preferred
collagenous materials have the same surface functional groups as do Type I and Type IV
15 natural collagens. Those functional groups are typically of the type which bind to acrylate-
type linkages.

The outer collagenous or proteinaceous coating may further contain additional
materials which have one or more functions, including, but not limited to, reducing friction,
providing a therapeutic for local or blood borne delivery, or enhancing thrombosis,
20 coagulation, or platelet activity. The additional materials may be applied either as a
substantially pure layer over the collagenous layer or chemically bonded to (and
interspersed with) the collagenous layer or physically bonded to the outer collagenous layer
The added bio-active materials may be, e.g., genes, growth factors, biomolecules, peptides,
oligonucleotides, members of the integrin family, RGD-containing sequences,
25 oligopeptides, e.g., fibronectin, laminin, vitronectin, hyaluronic acid, silk-elastin, elastin,
fibronectin, and other basement membrane proteins with bioactive agents.

Non-limiting examples of bioactive coatings or materials suitable in this invention
include both natural and synthetic compounds, e.g., fibrinogen, other plasma proteins,
growth factors (e.g., vascular endothelial growth factor, "VEGF"), synthetic peptides of
30 these and other proteins having attached RGD (arginine-glycine-aspartic acid) residues
generally at one or both termini, or other cell adhesion peptides, i.e., GRGDY,
oligonucleotides, full or partial DNA constructs, natural or synthetic phospholipids, or
polymers with phosphorylcholine functionality.

Other bioactive materials which may be used in the present invention include, for example, pharmaceutically active compounds, proteins, oligonucleotides, ribozymes, antisense genes, DNA compacting agents, gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids), nucleic acids (including, for example, naked DNA, cDNA, RNA, DNA, cDNA or RNA in a non-infectious vector or in a viral vector which may have attached peptide targeting sequences; antisense nucleic acid (RNA or DNA); and DNA chimeras which include gene sequences and encoding for ferry proteins such as membrane translocating sequences ("MTS") and herpes simplex virus-1 ("VP22")), and viral, liposomes and cationic polymers that are selected from a number of types depending on the desired application, including retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, and the like. For example, biologically active solutes include anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, PPACK (dextrophenylalanine proline arginine chloromethylketone), rapamycin, probucol, and verapamil; angiogenic and anti-angiogenic agents; anti-proliferative agents such as enoxaprin, angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin anticodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet factors; vascular cell growth promoters such as growth factors, growth factor receptor antagonists, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directly against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents;

vasodilating agents; agents which interfere with endogenous vascoactive mechanisms, and combinations thereof. These and other compounds are applied to the stenting device.

Polynucleotide sequences useful in practice of the invention include DNA or RNA sequences having a therapeutic effect after being taken up by a cell. Examples of therapeutic polynucleotides include anti-sense DNA and RNA; DNA coding for an anti-sense RNA; or DNA coding for tRNA or rRNA to replace defective or deficient endogenous molecules. The polynucleotides of the invention can also code for therapeutic polypeptides. A polypeptide is understood to be any translation production of a polynucleotide regardless of size, and whether glycosylated or not. Therapeutic polypeptides include as a primary example, those polypeptides that can compensate for defective or deficient species in an animal, or those that act through toxic effects to limit or remove harmful cells from the body. In addition, the polypeptides or proteins that can be incorporated into the polymer coating 130, or whose DNA can be incorporated, include without limitation, proteins competent to induce angiogenesis, including factors such as, without limitation, acidic and basic fibroblast growth factors, vascular endothelial growth factor (including VEGF-2, VEGF-3, VEGF-A, VEGF-B, VEGF-C) hif-1 and other molecules competent to induce an upstream or downstream effect of an angiogenic factor; epidermal growth factor, transforming growth factor α and β , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α , hepatocyte growth factor and insulin like growth factor; growth factors; cell cycle inhibitors including CDK inhibitors; thymidine kinase ("TK") and other agents useful for interfering with cell proliferation, including agents for treating malignancies; and combinations thereof. Still other useful factors, which can be provided as polypeptides or as DNA encoding these polypeptides, include monocyte chemoattractant protein ("MCP-1"), and the family of bone morphogenic proteins ("BMP's"). The known proteins include BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively or, in addition, molecules capable of inducing an upstream or

downstream effect of a BMP can be provided. Such molecules include any of the
5 “hedgehog” proteins, or the DNA’s encoding them.

In one exemplary embodiment of the present invention, the medical device has recombinant nucleic acid incorporated therein, wherein the recombinant nucleic acid comprises a viral vector having linked thereto an exogenous nucleic acid sequence.

“Exogenous nucleic acid sequence” is used herein to mean a sequence of nucleic acids that
10 is exogenous to the virus from which the vector is derived. The concentration of the viral vector, preferably an adenoviral vector, is at least about 10^{10} plaque forming units (“p.f.u.”), preferably at least about 10^{11} p.f.u. Alternatively, the concentration of the viral vector is limited by the concentration that results in an undesirable immune response from a patient.

Treatment of vaso-occlusive coils with the described materials may be carried out
15 using known methods, for example dip coating, spray coating, wiping, vapor deposition or the like.

The devices that are treated according to the procedure of this invention are often introduced to a selected site using the procedure outlined below. This procedure may be used in treating a variety of maladies. For instance, in treatment of an aneurysm, the
20 aneurysm itself may be filled with the devices made according to the procedure specified here. Shortly after the devices are placed within the aneurysm, an emboli begins to form and, at some later time, is at least partially replaced by cellular material formed around the vaso-occlusive devices.

In general, a selected site is reached through the vascular system using a collection
25 of specifically chosen catheters and guide wires. It is clear that should the aneurysm be in a remote site, e.g., in the brain, methods of reaching this site are somewhat limited. One widely accepted procedure is found in U.S. Patent No. 4,994,069 to Ritchart, et al. It utilizes a fine endovascular catheter such as is found in U.S. Patent No. 4,739,768, to Engelson. First of all, a large catheter is introduced through an entry site in the vasculature.
30 Typically, this would be through a femoral artery in the groin. Other entry sites sometimes chosen are found in the neck and are in general well known by physicians who practice this type of medicine. Once the introducer is in place, a guiding catheter is then used to provide a safe passageway from the entry site to a region near the site to be treated. For instance, in

5 treating a site in the human brain, a guiding catheter would be chosen which would extend from the entry site at the femoral artery, up through the large arteries extending to the heart, around the heart through the aortic arch, and downstream through one of the arteries extending from the upper side of the aorta. A guidewire and neurovascular catheter such as that described in the Engelson patent are then placed through the guiding catheter as a unit. Once the tip of the guidewire reaches the end of the guiding catheter, it is then extended
10 using fluoroscopy, by the physician to the site to be treated using the vaso-occlusive devices of this invention. During the trip between the treatment site and the guide catheter tip, the guidewire is advanced for a distance and the neurovascular catheter follows. Once both the distal tip of the neurovascular catheter and the guidewire have reached the treatment site, and the distal tip of that catheter is appropriately situated, *e.g.*, within the
15 mouth of an aneurysm to be treated, the guidewire is then withdrawn. The neurovascular catheter then has an open lumen to the outside of the body. The devices of this invention are then pushed through the lumen to the treatment site. They are held in place variously because of their shape, size, or volume. These concepts are described in the Ritchart et al patent as well as others. Once the vaso-occlusive devices are situated in the vascular site,
20 the embolism forms.

Modifications of the procedure and device described above, and the methods of using them in keeping with this invention will be apparent to those having skill in this mechanical and surgical art. These variations are intended to be within the scope of the claims that follow.

CLAIMS5 WE CLAIM AS OUR INVENTION:

1. A vaso-occlusive device comprising:
 - a) a vaso-occlusive member;
 - b) an inner tie layer or treatment on at least a portion of said vaso-occlusive member; and
 - 10 c) a protein-based outer coating on said inner coating.
2. The device of claim 1 wherein the protein-based outer coating is collagen-based.
3. The device of claim 1 wherein the vaso-occlusive member is a metallic element comprising an elongated helical coil.
- 15 4. The device of claim 3 wherein the coil is a cylindrical helical coil.
5. The device of claim 3 wherein the coil comprises a metal selected from gold, rhenium, platinum, palladium, rhodium, ruthenium, stainless steel, tungsten, titanium, nickle, and alloys thereof.
6. The device of claim 1 wherein the inner coating is a polymer-based agent.
- 20 7. The device of claim 6 wherein the inner coating is bonded to said vaso-occlusive member.
8. The device of claim 7 wherein the inner coating is applied by a procedure selected from the group consisting of applying a silane coupling agent, applying a acrylate-based coupling agent, plasma deposition, plasma etching, applying a low molecular weight adhesive agent, vapor deposition, and polymer coating from a dilute solution.
- 25 9. The device of claim 8 wherein the inner coating is created by plasma treatment.
10. The device of claim 1 wherein said outer coating is photo-polymerizable.

11. The device of claim 8 wherein the inner coating is paraxylylene and
5 deposited by vapor deposition.

12. The device of claim 1 further comprising a bioactive material selected from
the group consisting of genes, growth factors, biomolecules, peptides, oligonucleotides,
members of the integrin family, RGD-containing sequences, oligopeptides, e.g.,
fibronectin, laminin, vitronectin, hyaluronic acid, silk-elastin, elastin, infibrogen, and other
10 basement membrane proteins with bioactive agents.

13. The device of claim 12 wherein said bioactive material is a coating on said
protein-based outer coating.

14. The device of claim 12 wherein said bioactive material is intermixed with
said protein-based outer coating.

15. A vaso-occlusive device comprising:

- a) a vaso-occlusive member, and
- b) a protein-based outer coating on said vaso-occlusive member.

16. The device of claim 15 wherein the protein-based outer coating is collagen-
based.

17. The device of claim 15 wherein the vaso-occlusive member is a metallic
20 element comprising an elongated helical coil.

18. The device of claim 17 wherein the coil is a cylindrical helical coil.

19. The device of claim 18 wherein the coil comprises a metal selected from
gold, rhenium, platinum, palladium, rhodium, ruthenium, stainless steel, tungsten, titanium,
25 nickle, and alloys thereof.

20. The device of claim 15 wherein said outer coating is photo-polymerizable.

21. The device of claim 15 wherein the bioactive material is selected from the group consisting of genes, growth factors, biomolecules, peptides, oligonucleotides, members of the integrin family, RGD-containing sequences, oligopeptides, e.g., fibronectin, laminin, vitronectin, hyaluronic acid, silk-elastin, elastin, infibrogen, and other basement membrane proteins with bioactive agents.

22. The device of claim 15 further comprising fibrous material attached to the vaso-occlusive member that is also at least partially covered by said protein-based outer coating.

23. The device of claim 18 further comprising fibrous material attached to the vaso-occlusive member that is also at least partially covered by said protein-based outer coating.

24. The device of claim 23 wherein said fibrous material comprises one or more polymers.

25. The device of claim 24 wherein said one or more polymers is selected from the group consisting of polyglycolic acid, polylactic acid, reconstituted collagen, poly-*p*-dioxanone, and their copolymers such as poly(glycolide-lactide) copolymer, poly(glycolide-trimethylene carbonate) copolymer, poly(glycolide- ϵ -caprolactone) copolymer, glycolide-trimethylene carbonate triblock copolymer, and mixtures.

26. A vaso-occlusive device comprising:

- a) a vaso-occlusive member having a flexibility; and
- b) a protein-based outer coating on said vaso-occlusive member in such amount and thickness that the flexibility of the vaso-occlusive device is not more than 35% stiffer than said vaso-occlusive member.

27. The device of claim 26 wherein the protein-based outer coating is collagen-based.

28. The device of claim 27 wherein the vaso-occlusive device is not more than 1
5 0% stiffer than said vaso-occlusive member.

29. The device of claim 26 wherein the vaso-occlusive member is a metallic
element comprising an elongated helical coil.

30. The device of claim 29 wherein the coil is a cylindrical helical coil.

31. The device of claim 29 wherein the coil comprises a metal selected from
10 gold, rhenium, platinum, palladium, rhodium, ruthenium, stainless steel, tungsten, titanium,
nickle, and alloys thereof.

32. The device of claim 26 wherein said outer coating is photo-polymerizable.

33. The device of claim 26 further comprising fibrous material attached to the
vaso-occlusive member that is also at least partially covered by said protein-based outer
15 coating.

34. The device of claim 26 further comprising a bioactive material selected from
the group consisting of genes, growth factors, biomolecules, peptides, oligonucleotides,
members of the integrin family, RGD-containing sequences, oligopeptides, e.g.,
fibronectin, laminin, bitronectin, hyaluronic acid, silcolastin, fibrogenin, and other
20 basement proteins with bioactive agents.

35. The device of claim 34 wherein said bioactive material is a coating.

36. The device of claim 34 wherein said bioactive material is intermixed with
said protein-based coating.

37. The device of claim 33 wherein said fibrous material comprises one or more
25 polymers.

38. The device of claim 37 wherein said one or more polymers is selected from
the group consisting of polyglycolic acid, polylactic acid, reconstituted collagen, poly-*p*-

dioxanone, and their copolymers such as poly(glycolide-lactide) copolymer,
5 poly(glycolide-trimethylene carbonate) copolymer, poly(glycolide- ϵ -caprolactone)
copolymer, glycolide-trimethylene carbonate triblock copolymer, and mixtures.

39. A vaso-occlusive device comprising:

- a) a vaso-occlusive member;
- b) an inner tie layer or treatment on at least a portion of said vaso-occlusive
10 member; and
- c) a bioactive-material-based outer coating on said inner coating.

40. The device of claim 39 wherein the vaso-occlusive member is a metallic
element comprising an elongated helical coil.

41. The device of claim 39 wherein the coil is a cylindrical helical coil.

15 42. The device of claim 41 wherein the coil comprises a metal selected from
gold, rhenium, platinum, palladium, rhodium, ruthenium, stainless steel, tungsten, titanium,
nickle, and alloys thereof.

20 43. The device of claim 39 wherein the inner coating is applied by a procedure
selected from the group consisting of applying a silane coupling agent, applying a acrylate-
based coupling agent, plasma deposition, plasma etching, applying a low molecular weight
adhesive agent, vapor deposition, and polymer coating from a dilute solution.

44. The device of claim 43 wherein the inner coating is created by plasma
treatment.

25 45. The device of claim 43 wherein the inner coating is paraxylylene and
deposited by vapor deposition.

46. The device of claim 39 where in the bioactive material is selected from the
group consisting of genes, growth factors, biomolecules, peptides, oligonucleotides,
members of the integrin family, RGD-containing sequences, oligopeptides, e.g.,

5 fibronectin, laminin, vitronectin, hyaluronic acid, silk-elastin, elastin, infibrogen, and other basement membrane proteins with bioactive agents.

1/1




FIG. 1




FIG. 2

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L31/10 A61L31/16 A61L31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F A61L A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DE 196 47 280 A (KLEE DORIS DR ; LAHANN JOERG DIPL CHEM (DE); REUL JUERGEN PRIV DOZ) 23 October 1997 (1997-10-23)</p> <p>column 4, line 8 -column 5, line 14 claims</p> <p style="text-align: center;">--- -/--</p>	<p>1-9, 11-19, 21, 25-31, 34-36, 38-46</p>

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

13 March 2000

Date of mailing of the international search report

20/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6816 Patentplan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Thornton, S

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 36784 A (COOK INC) 27 August 1998 (1998-08-27) page 9, line 22 - line 28 page 11, line 5 - line 17 page 17, line 5 -page 19, line 18 claims	1-9, 11-19, 21, 25-31, 34-36, 38-46
P,X	US 5 980 550 A (EDER JOSEPH C. ET AL) 9 November 1999 (1999-11-09) claims	1-9, 12-19, 21-31, 33-44, 46

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/26556

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19647280	A	23-10-1997	DE 29518932 U	20-06-1996
WO 9836784	A	27-08-1998	AU 6663298 A	09-09-1998
			EP 0968013 A	05-01-2000
US 5980550	A	09-11-1999	WO 9965401 A	23-12-1999